Recent News
Read ArticleWhile adult rheumatology fellowships have surged in popularity and become quite competitive, more than half of pediatric rheumatology fellowship positions went unfilled in 2024, according to the National Resident Matching Program (NRMP).
Healthy diet helps chronic pain
Chronic pain is an acute and debilitating condition that affects millions of people worldwide. And while pain interventions are available, many people struggle without treatment at all.
Read Article
ICYMI: GLP-1 Agonists Show Promise in Slowing Kidney Disease in Lupus Nephritis
A retrospective cohort study presented at #ACR24 explores the benefits of GLP-1Ras in reducing the risk of end-stage renal disease (ESRD) for patients with lupus nephritis. Drawing on data from the TrinetX global research database, the study examines how GLP-1Ras may reduce ESRD progression in a population where 10-20% progress to ESRD within five years, even with immunosuppressive therapies.
Read Article
Join us at RheumNow Live February 8 & 9 in Dallas, TX!
Our incredible meeting will feature speakers like:
Rheumatology Power Trio: Exploring RA Management in Older Adults, AI Innovations, and Multimorbidity Strategies
Una Makris, MD, MSc
Jeff Curtis, MD, MS, MPH
Bryant… https://t.co/7WawLxwBLP https://t.co/GdBnGkHk9i
Dr. John Cush @RheumNow ( View Tweet)
ACR24 IL-17 Panel
Join Dr. Philip Mease, Dr. Brian Jaros and Dr. Peter Nash as they discuss key takeaways on IL-17 presentations and data presented at the 2024 ACR Convergence meeting in Washington, DC.
https://t.co/04bW7vaMTQ https://t.co/0rTglbW75u
Links:
Dr. John Cush @RheumNow ( View Tweet)
2024 Match results are in - Rheumatology- 287 matched, 99%: Top 6:
1. Cardi 99.8%
2. Cardio EP 98%
3. Endocrinology 98.4 %
4. GI 99.6%
5. Heme/Onc 99.7%
6. Rheum 99% https://t.co/PBuQPIQaqo https://t.co/xcGbLiEdSw
Dr. John Cush @RheumNow ( View Tweet)
Chikungunya marches on, at a cost
A recent article from BMC Global Health suggests that between 2011 and 2020, the mosquito-borne disease chikungunya, has disabled millions and likely amassed close to $50 billion in healthcare and disability-related costs in 110 countries.
Read Article
ICYMI: SELECT-GCA suggests JAKis may be the new kid on the block
Clinicians treating giant cell arteritis (GCA) have long had to contend with a disappointingly limited selection of drugs from which to select. A new group of drugs is finally showing promise in the treatment of GCA.
Read Article
Navigating Rheumatology Care in Humanitarian Crisis Settings
Dr. Antoni Chan talks with Dr. Martha Dhzhus, who presented Thursday at the Global Summit about rheumatology care in the Ukraine, at the 2024 ACR Convergence meeting in Washington, DC.
https://t.co/k4YTVFnTiF https://t.co/bScrJ28rKi
Dr. John Cush @RheumNow ( View Tweet)
Metabolic syndrome assoc w/ with response rates in #RA (CDAI MCID OR 0.6), on or off TNFi. Adipokines were associated with metabolic syndrome but were not associated with clinical responses. Data from CERTAIN cohort & CorEvitas registry https://t.co/YH44iTwYTr https://t.co/ec3vb266ym
Dr. John Cush @RheumNow ( View Tweet)
Lancet forecasts that in Australia 5.4 million will have arthritis 2040, a 31% increase 4.1 mill in 2025. Included 3.2 w/ OA, ~750K w/ RA, & 8500 w/ JIA. OA incr in males from 6.3% to 7% (2040). & 10.8 to 12.2% in F. RA will grow from 1.56 to 1.75% in males and 2.6 to 2.9% in… https://t.co/6DM0ZLlZ05 https://t.co/djPP1cUDOI
Dr. John Cush @RheumNow ( View Tweet)
Although there is a bidirectional relationship betw pain and sleep, Sleep impairment more strongly predicts pain than pain does sleep. Addressing sleep disturbances is crucial, as it is linked to higher levels of disability, depression, pain-related catastrophizing.… https://t.co/MaW706l6rn https://t.co/szqVcrn5Mt
Dr. John Cush @RheumNow ( View Tweet)
Summary of JAKi Studies
Dr. Peter Nash, at the 2024 ACR Convergence meeting in Washington, DC, talks about JAKi data presented in: the SELECT-GCA trial and safety signals; ILD; cancer; cycling; RA; uveitis; and new JAKs under study.
https://t.co/ywmtrTi0iF https://t.co/nbFFojL1i4
Dr. John Cush @RheumNow ( View Tweet)
Challenge in Measuring Cutaneous Lupus Activity and Severity
JAMA Dermatology features a discussion by Drs. McMichael and Frey on measuring lupus skin disease in clinical trials and practice using the validated Cutaneous Lupus Erythematosus Disease Area and Severity Index… https://t.co/qyZPDzUduO https://t.co/cCoc3sWCJy
Dr. John Cush @RheumNow ( View Tweet)
Infertility linked to post-childbrith onset of systemic autoimmune disease
Women who experience infertility but do not use fertility treatments have a higher risk of developing a group of conditions called systemic autoimmune rheumatic diseases (SARD) in the nine years after a… https://t.co/NJf44KJ2Hc https://t.co/W4rhsDHoqB
Dr. John Cush @RheumNow ( View Tweet)
BMJ has published an extensive, full read review of the Advances in the management of psoriatic arthritis in adults - by Drs. Gladman and Kharouf, (great read and reference!) https://t.co/4Bz3Vq93jH https://t.co/ZhwKZ4XmNy
Dr. John Cush @RheumNow ( View Tweet)
JAMA FULL READ review and overview of Axial Spondyloarthritis by Drs. Deodhar & Bittar
- Dx often delayed 6-8 yrs
- Sensitivity/Specificity of: HLA-B27 (50%/90%), CRP (35%/91%), Xray sacroiliitis (66%/68%) or MRI (78%/88%). Great tables, figs, Xrays &Reference!… https://t.co/UbqVOr2iDx https://t.co/Ye5mYcbYX2
Dr. John Cush @RheumNow ( View Tweet)
Fibroblastic Rheumatism - JAMA Case: 50yoM w/ 3 yr hx of periarticular nodules, symmetric polyarthralgia at B/L PIPs. These were painful with manipulation or minor trauma. Labs negative. https://t.co/dWvBjXgAIh https://t.co/YWmdqJrijf
Dr. John Cush @RheumNow ( View Tweet)
Primary Hypophosphatemia (HYPOPH) - Japan study 50,136 adults w/ 424,434 alk phosphatase (ALP) tests. Persistent HYPOPH seen in 0.54% (273) due to cancer(30%), steroids(21%), DMARDs (16%). Unexplained HYPOPH had pain, muscle weakness, fatigue & could have primary HYPOPH… https://t.co/kGPSXSYEZI https://t.co/RtwSRnzeU0
Dr. John Cush @RheumNow ( View Tweet)
Another Stelara (Ustekinumab) biosimilar was FDA approved on 12/1 -- called Yesintek for the treatment of Crohn’s, Ulcerative Colitis, Psoriasis & PsA. This makes 6 FDA approved biosimilars for ustekinumab.https://t.co/SMKx1LnBB1 https://t.co/96u5YuvyIf
Dr. John Cush @RheumNow ( View Tweet)
Ozempic will change rheumatology @drdavidliew
Ozempic is everywhere. Even all the way in Australia, where we have highly constrained supply that makes headlines and substantial limits on direct-to-consumer advertising, somehow I know the jingle from the American ad for Ozempic.… https://t.co/4gujykjDCa https://t.co/RLG1vA57kC
Dr. John Cush @RheumNow ( View Tweet)
From the blog
How would you manage a patient with Overlap (anti-synthetase) syndrome, ILD, polyarthritis and myositis?
Podcasts
Don’t Buy Guitars (12.6.2024)
ACR24 IL-17 Topic Panel Advancing Care with IL-17 Pathway Insights
ACR24 JAK TYK Topic Panel
ACR24 RA Panel Key Discussions on Rheumatoid Arthritis
Poster Hall
